CDA | Evidence Driven
CDA | Evidence Driven

Elosulfase alfa

Details

Files
Generic Name:
Elosulfase alfa
Project Status:
Complete
Therapeutic Area:
Mucopolysaccharidosis IVA (Morquio A syndrome)
Manufacturer:
BioMarin Pharmaceutical (Canada) Inc.
Call for patient/clinician input open:
Brand Name:
Vimizim
Project Line:
Reimbursement Review
Project Number:
SR0389-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Mucopolysaccharidosis IVA (Morquio A syndrome)
Recommendation Type:
Do not list
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Clinical Report View PDF
Pharmacoeconomic Report View PDF
Patient Group Input Submissions View PDF
Last Updated : August 5, 2014